Sector News

Amid Novartis spinoff efforts, Sandoz pledges $400M for biosimilar manufacturing in Slovenia

March 11, 2023
Life sciences

Novartis may be in the process of spinning out its generics and biosimilar outfit, Sandoz, but that doesn’t mean the latter company is pausing manufacturing investments. In fact, it’s quite the opposite.

Sandoz revealed plans to spend at least $400 million on a new biologics plant in Slovenia. The site, set to be built in Lendava, will support the company’s biosimilar ambitions, according to a Thursday release.

The project will be one of the largest international private sector investments in Slovenia, Sandoz said. Thursday, the company’s CEO, Richard Saynor, attended a signing ceremony for a memorandum of understanding with Slovenian Prime Minister Robert Golob, Ph.D.

Sandoz expects construction to start this year. The plant should be ready to run by late 2026, according to the press release.

In terms of biosimilars, Sandoz already sells eight products in various disease areas such as immunology and oncology. The company also touts a pipeline of more than 15 molecules in development.

Sandoz’s split from parent company Novartis was announced last August. At the time, the spinoff was expected to wrap up by the second half of 2023, according to a press release.

The Slovenia development isn’t Sandoz’s only manufacturing play in Europe in recent months. Back in November, the company said it would spend 50 million euros to expand its antibiotics manufacturing site in Kundl, Austria. With that pledge, the company had committed to spending at least 250 million euros on European antibiotics manufacturing over the last few years.

By Eric Sagonowsky

Source: fiercepharma.com

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach